Voluntis received marketing authorization from the FDA for its digital app to aid patients suffering from different types of cancer. The mobile app, called Oleena, is designed to provide users with real-time, adaptive recommendations to help them manage their symptoms on a daily basis. Combined with remote patient monitoring and care team support, it aims to better manage the distressing, common events and side effects (nausea, pain, and diarrhea) that hinder the quality of life. Voluntis is hopeful that the app will reduce unnecessary hospitalizations. The app was categorized as a Class II medical device by the FDA. It can also be used to supply on-demand directions for initiation and dosing of supportive therapies based on a patient’s previously set care
plan. It is designed to guide patients through diagnosis and anticancer treatments such as chemotherapy, targeted therapies, and immunotherapy.
“Beyond monitoring their symptoms, we believe that empowering patients via the digital delivery of real-time and personalized therapeutic interventions offers the opportunity for significant clinical and economic outcomes,” CEO Pierre Leurent said in a statement.
Voluntis had previously collaborated with Roche Pharma France on a similar product focused on breast cancer but the collaboration fell through earlier this year.